Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial

John B. Kostis, Stuart Cobbe, Colin Johnston, Ian Ford, Michael Murphy, Michael A. Weber, Henry R. Black, Pierre Francois Plouin, Daniel Levy, Guiseppe Mancia, Pierre Larochelle, Rainer E. Kolloch, Michael Alderman, Luis Miguel Ruilope, Björn Dahlöf, John M. Flack, Robert Wolf

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial is a large clinical trial of omapatrilat, a vasopeptidase inhibitor, in patients with stage 1 isolated systolic hypertension (ISH). OPERA is the first study to examine whether effective antihypertensive treatment can provide survival and clinical end point benefits in older persons with this common condition. This 5-year multinational, randomized, double-blind, parallel-group, placebo-controlled, forced-titration study will be conducted in approximately 12,600 subjects randomized by approximately 1100 study centers worldwide over a recruitment period of approximately 2 years. The primary objective of OPERA is to determine whether treatment with once-daily omapatrilat (target dose 40 mg) will reduce cardiovascular (CV) morbidity and mortality in older (≥65 years) men and women with enhanced risk for atherosclerotic events due to stage 1 ISH plus other risk factors for which currently there is no evidence-based requirement for treatment. Blood pressure inclusion criteria are systolic blood pressure (SBP) 140 to 159 mm Hg (SBP 125 to 139 mm Hg in diabetic individuals) and diastolic blood pressure (DBP)

Original languageEnglish
Pages (from-to)193-198
Number of pages6
JournalAmerican Journal of Hypertension
Volume15
Issue number2 I
DOIs
Publication statusPublished - 2002

Fingerprint

Blood Pressure
Hypertension
omapatrilat
Antihypertensive Agents
Therapeutics
Placebos
Clinical Trials
Morbidity
Survival
Mortality

Keywords

  • Cardiovascular morbidity and mortality
  • Isolated systolic hypertension
  • Omapatrilat

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Kostis, J. B., Cobbe, S., Johnston, C., Ford, I., Murphy, M., Weber, M. A., ... Wolf, R. (2002). Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial. American Journal of Hypertension, 15(2 I), 193-198. https://doi.org/10.1016/S0895-7061(01)02048-9

Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial. / Kostis, John B.; Cobbe, Stuart; Johnston, Colin; Ford, Ian; Murphy, Michael; Weber, Michael A.; Black, Henry R.; Plouin, Pierre Francois; Levy, Daniel; Mancia, Guiseppe; Larochelle, Pierre; Kolloch, Rainer E.; Alderman, Michael; Ruilope, Luis Miguel; Dahlöf, Björn; Flack, John M.; Wolf, Robert.

In: American Journal of Hypertension, Vol. 15, No. 2 I, 2002, p. 193-198.

Research output: Contribution to journalArticle

Kostis, JB, Cobbe, S, Johnston, C, Ford, I, Murphy, M, Weber, MA, Black, HR, Plouin, PF, Levy, D, Mancia, G, Larochelle, P, Kolloch, RE, Alderman, M, Ruilope, LM, Dahlöf, B, Flack, JM & Wolf, R 2002, 'Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial', American Journal of Hypertension, vol. 15, no. 2 I, pp. 193-198. https://doi.org/10.1016/S0895-7061(01)02048-9
Kostis, John B. ; Cobbe, Stuart ; Johnston, Colin ; Ford, Ian ; Murphy, Michael ; Weber, Michael A. ; Black, Henry R. ; Plouin, Pierre Francois ; Levy, Daniel ; Mancia, Guiseppe ; Larochelle, Pierre ; Kolloch, Rainer E. ; Alderman, Michael ; Ruilope, Luis Miguel ; Dahlöf, Björn ; Flack, John M. ; Wolf, Robert. / Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial. In: American Journal of Hypertension. 2002 ; Vol. 15, No. 2 I. pp. 193-198.
@article{9b3b8c06ea0347359a5163925e824583,
title = "Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial",
abstract = "The Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial is a large clinical trial of omapatrilat, a vasopeptidase inhibitor, in patients with stage 1 isolated systolic hypertension (ISH). OPERA is the first study to examine whether effective antihypertensive treatment can provide survival and clinical end point benefits in older persons with this common condition. This 5-year multinational, randomized, double-blind, parallel-group, placebo-controlled, forced-titration study will be conducted in approximately 12,600 subjects randomized by approximately 1100 study centers worldwide over a recruitment period of approximately 2 years. The primary objective of OPERA is to determine whether treatment with once-daily omapatrilat (target dose 40 mg) will reduce cardiovascular (CV) morbidity and mortality in older (≥65 years) men and women with enhanced risk for atherosclerotic events due to stage 1 ISH plus other risk factors for which currently there is no evidence-based requirement for treatment. Blood pressure inclusion criteria are systolic blood pressure (SBP) 140 to 159 mm Hg (SBP 125 to 139 mm Hg in diabetic individuals) and diastolic blood pressure (DBP)",
keywords = "Cardiovascular morbidity and mortality, Isolated systolic hypertension, Omapatrilat",
author = "Kostis, {John B.} and Stuart Cobbe and Colin Johnston and Ian Ford and Michael Murphy and Weber, {Michael A.} and Black, {Henry R.} and Plouin, {Pierre Francois} and Daniel Levy and Guiseppe Mancia and Pierre Larochelle and Kolloch, {Rainer E.} and Michael Alderman and Ruilope, {Luis Miguel} and Bj{\"o}rn Dahl{\"o}f and Flack, {John M.} and Robert Wolf",
year = "2002",
doi = "10.1016/S0895-7061(01)02048-9",
language = "English",
volume = "15",
pages = "193--198",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "2 I",

}

TY - JOUR

T1 - Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial

AU - Kostis, John B.

AU - Cobbe, Stuart

AU - Johnston, Colin

AU - Ford, Ian

AU - Murphy, Michael

AU - Weber, Michael A.

AU - Black, Henry R.

AU - Plouin, Pierre Francois

AU - Levy, Daniel

AU - Mancia, Guiseppe

AU - Larochelle, Pierre

AU - Kolloch, Rainer E.

AU - Alderman, Michael

AU - Ruilope, Luis Miguel

AU - Dahlöf, Björn

AU - Flack, John M.

AU - Wolf, Robert

PY - 2002

Y1 - 2002

N2 - The Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial is a large clinical trial of omapatrilat, a vasopeptidase inhibitor, in patients with stage 1 isolated systolic hypertension (ISH). OPERA is the first study to examine whether effective antihypertensive treatment can provide survival and clinical end point benefits in older persons with this common condition. This 5-year multinational, randomized, double-blind, parallel-group, placebo-controlled, forced-titration study will be conducted in approximately 12,600 subjects randomized by approximately 1100 study centers worldwide over a recruitment period of approximately 2 years. The primary objective of OPERA is to determine whether treatment with once-daily omapatrilat (target dose 40 mg) will reduce cardiovascular (CV) morbidity and mortality in older (≥65 years) men and women with enhanced risk for atherosclerotic events due to stage 1 ISH plus other risk factors for which currently there is no evidence-based requirement for treatment. Blood pressure inclusion criteria are systolic blood pressure (SBP) 140 to 159 mm Hg (SBP 125 to 139 mm Hg in diabetic individuals) and diastolic blood pressure (DBP)

AB - The Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial is a large clinical trial of omapatrilat, a vasopeptidase inhibitor, in patients with stage 1 isolated systolic hypertension (ISH). OPERA is the first study to examine whether effective antihypertensive treatment can provide survival and clinical end point benefits in older persons with this common condition. This 5-year multinational, randomized, double-blind, parallel-group, placebo-controlled, forced-titration study will be conducted in approximately 12,600 subjects randomized by approximately 1100 study centers worldwide over a recruitment period of approximately 2 years. The primary objective of OPERA is to determine whether treatment with once-daily omapatrilat (target dose 40 mg) will reduce cardiovascular (CV) morbidity and mortality in older (≥65 years) men and women with enhanced risk for atherosclerotic events due to stage 1 ISH plus other risk factors for which currently there is no evidence-based requirement for treatment. Blood pressure inclusion criteria are systolic blood pressure (SBP) 140 to 159 mm Hg (SBP 125 to 139 mm Hg in diabetic individuals) and diastolic blood pressure (DBP)

KW - Cardiovascular morbidity and mortality

KW - Isolated systolic hypertension

KW - Omapatrilat

UR - http://www.scopus.com/inward/record.url?scp=0036175311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036175311&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(01)02048-9

DO - 10.1016/S0895-7061(01)02048-9

M3 - Article

VL - 15

SP - 193

EP - 198

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 2 I

ER -